Comorbidity of Depression and Constipation Clinical Trial
Official title:
Effect of Probiotic on Chinese Patients With Depression and Constipated Comorbidity
Depressive disorder, also known as depression, is a type of mood disorder characterized by persistent low mood. The incidence of depression worldwide is about 6%. The high comorbidity rate between depression and constipation indicated the role of the gut-brain axis in depression. Growing evidence suggested that the gut microbiota plays a key role in the development of depression. Probiotics can effectively improve constipation and regulate gut microbiota, and showed potential in alleviating depression. This study investigated the effect of formula probiotic (containing Lactobacillus paracasei, Bifidobacterium animals, Bifidobacterium longum, Bifidobacterium bifidum, and Lactobacillus plantarum) on the comorbidity of depression and constipation.
| Status | Not yet recruiting |
| Enrollment | 200 |
| Est. completion date | December 30, 2021 |
| Est. primary completion date | June 30, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 70 Years |
| Eligibility |
Inclusion Criteria: - Normal body mass index = 18.5 until = 29.9 - Hamilton Rating Scale for Depression (HAMD-17) score not less than 8 - Meet the ROME III criteria for functional constipation - Agreed to intake study product during the study period - Agreed to sign written informed consent Exclusion Criteria: - Use of systemic antibiotics or antimycotics medication in the 30 days prior to the study - Investigator's uncertainty about the willingness or ability of subject to comply with the protocol requirements - Persons with a milk protein allergy, lactose intolerance - Pregnant or breastfeeding women - Subject had other serious diseases |
| Country | Name | City | State |
|---|---|---|---|
| China | The Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine | Nanjing | Jiangsu |
| Lead Sponsor | Collaborator |
|---|---|
| China Agricultural University | The Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine |
China,
Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, Ota M, Koga N, Hattori K, Kunugi H. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J Affect Disord. 2016 Sep 15; — View Citation
Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, Jafari P, Akbari H, Taghizadeh M, Memarzadeh MR, Asemi Z, Esmaillzadeh A. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, — View Citation
Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, de Graaf R, Demyttenaere K, Hu C, Iwata N, Karam AN, Kaur J, Kostyuchenko S, Lépine JP, Levinson D, Matschinger H, Mora ME, Browne MO, Posada-Villa J, Viana MC, Williams DR, Kessler RC. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011 Jul 26;9:90. doi: 10.1186/1741-7015-9-90. — View Citation
De Palma G, Blennerhassett P, Lu J, Deng Y, Park AJ, Green W, Denou E, Silva MA, Santacruz A, Sanz Y, Surette MG, Verdu EF, Collins SM, Bercik P. Microbiota and host determinants of behavioural phenotype in maternally separated mice. Nat Commun. 2015 Jul 28;6:7735. doi: 10.1038/ncomms8735. — View Citation
Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr. 2019 Apr;38(2):522-528. doi: 10.1016/j.cln — View Citation
Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The Central Nervous System and the Gut Microbiome. Cell. 2016 Nov 3;167(4):915-932. doi: 10.1016/j.cell.2016.10.027. Review. — View Citation
Walker EA, Katon WJ, Jemelka RP, Roy-Bryne PP. Comorbidity of gastrointestinal complaints, depression, and anxiety in the Epidemiologic Catchment Area (ECA) Study. Am J Med. 1992 Jan 24;92(1A):26S-30S. — View Citation
Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry. 2017 Feb 20;16:14. doi: 10.1186/s12991-017-0138-2. eCollection 2017. Review. Erratum in: Ann Gen Psychiatry. 2017 Mar 7;16:18. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Hamilton Depression Rating Scale | Depressive symptoms as measured with the Hamilton Rating Scale for Depression. The score rangs from 0 to 53. The higher score means severer depressive symptoms. | Change from baseline score to intervention measurements at 4 and 8 weeks | |
| Secondary | Patient Assessment of Constipation Symptom | Constipation symptoms as measured with the Patient Assessment of Constipation Symptom. The score ranges from 0 to 48. The higher score means severer constipated symptoms. | changes from baseline score to intervention measurements at 4 and 8 weeks | |
| Secondary | Serum Il-1ß | Serum Il-1ß levels before and after intervention assessed by ELISA. | changes from baseline level to intervention measurements at 4 and 8 weeks | |
| Secondary | Serum Il-6 | Serum Il-6 levels before and after intervention assessed by ELISA. | changes from baseline level to intervention measurements at 4 and 8 weeks | |
| Secondary | Serum TNF-a | Serum TNF-a levels before and after intervention assessed by ELISA. | changes from baseline level to intervention measurements at 4 and 8 weeks | |
| Secondary | Serum cortisol | Serum cortisol levels before and after intervention assessed by ELISA. | changes from baseline level to intervention measurements at 4 and 8 weeks | |
| Secondary | Serum Brain-derived neurotrophic factor | Serum Brain-derived neurotrophic factor levels before and after intervention assessed by ELISA. | changes from baseline level to intervention measurements at 4 and 8 weeks | |
| Secondary | Serum concentrations of tryptophan metabolites | Serum concentrations of tryptophan metabolites quantified by High-Performance Liquid Chromatography and Mass Spectrometry | Changes from baseline level to intervention measurements at 4 and 8 weeks | |
| Secondary | Serum concentrations of bile acid | Quantification by High-Performance Liquid Chromatography and Mass Spectrometry | Changes from baseline level to intervention measurements at 4 and 8 weeks | |
| Secondary | Fecal microbiome | Fecal microbiome measured by next generation sequencing | Changes from baseline to intervention measurements at 4 and 8 weeks | |
| Secondary | Stool form | Stool form measured with the Bristol Stool Form Scale, which classify the form of human faeces into seven types, successively named type 1 to type 7. Types 1 and 2 indicate constipation, with 3 and 4 being the ideal stools as they are easy to defecate while not containing excess liquid, 5 indicating lack of dietary fiber, and 6 and 7 indicate diarrhoea. | Change from baseline score to intervention measurements at 4 and 8 weeks |